Aptinyx (NASDAQ:APTX) has announced positive preclinical data on its novel NMDA receptor modulator, NYX-458, showing reverse effects in a non-human primate model of Parkinson’s disease. As quoted in the press release: “With up to half of all people with Parkinson’s disease experiencing cognitive impairment and very few therapeutic options addressing these cognitive deficits, the unmet … Continued